NCT04551222CompletedPhase 2/3
The Re-Prosper HF Study
Treatment of Veterans With Heart Failure With Reduced Ejection Fraction With Probenecid
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
Heart failure with reduced ejection fraction (HFrEF) is a common cause for admission within the Veterans Affairs (VA) Health Care System. It is associated with severe impairment of physical and mental health status and carries a high risk of mortality. Even though significant progress has been made in understanding the disease process, currently, its management and treatment is limited. The investigators have discovered that a commonly used drug for the treatment of gout can be repurposed for the treatment of HFrEF. The objective of this study is the treatment of outpatient Veterans with HFrEF with probenecid to improve heart and health function. Specifically, the investigators are testing whether oral probenecid administered orally twice per day for 180 days improves heart function as measured via ultrasound of the heart (aim 1); improves exercise capacity (aim 2); and improves self-report heart failure specific health status as measured via questionnaires (aim 3).
- Status (registry)
- Completed
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 125 (actual)
- First submitted
- 9 Sept 2020
- Start date
- 9 Jun 2021
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- VA Office of Research and Development
- Diseases
- Heart failure
- NCT number
- NCT04551222
What you commit to
- Study type: Interventional · Phase 2/3
- Participants enrolled: 125
- From 9 Jun 2021 to the primary completion date, 31 Dec 2025
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Oral therapy with probenecid for any indication during the preceding 3 months.
- Hypersensitivity to probenecid based on prior exposure.
- Acute gout attack within the previous 3 months.
Other illness
- Acute coronary syndrome or cardiac revascularization within the past 3 months.
- Cardiac resynchronization therapy within the past 3 months.
- Constrictive pericarditis or restrictive cardiomyopathy on cardiac imaging study (echocardiogram cardiac MRI, cardiac CT) within the last 12 months.
- Ablation for cardiac arrhythmias within the past month.
- Uncorrected cyanotic congenital heart disease.
- Severe right sided valvular disease and/or greater than moderate degree of stenotic or regurgitant left valvular disease.
- Terminal illness with expected survival of less than 12 months.
- Inability to provide informed consent or study procedures due to dementia, unstable psychiatric disease, or other cause (e.g. inability to do perform exercise testing).
- History of uric acid kidney stones within the last year. Patient will be removed from the study if they develop urate kidney stones.
- History of blood diseases in the past year: Aplastic anemia, Hemolytic anemia, Leukopenia, Neutropenia, Pancytopenia, Thrombocytopenia or leukemia.
Lab values
- End stage renal disease with renal replacement therapy or creatinine clearance less than 30 ml/min \[17\].
- Peripartum cardiomyopathy diagnosed within past 6 months. If LVEF is still 40% after 6 months of diagnosis, they can be enrolled into the study.
- Creatinine clearance (eGFR) \<30 ml/min.
Age
- Women who are pregnant, breast feeding, or plan to become pregnant during the study. All women in childbearing age will undergo baseline and quarterly urine pregnancy tests to ensure absence of pregnancy since the cardiometabolic assessments will be different during pregnancy.
Who the study is looking for
- Have documented heart failure as a treated inpatient or outpatient diagnosis in the medical record.
- Left ventricular ejection 40% within the past 12 months either by echocardiogram, cardiac MRI, cardiac CT, nuclear imaging or cardiac catheterization.
- NYHA class II-III
- On stable GDMT for at least 2 weeks (including at least an EBM dose of betablocker and RAAS inhibition) consistent with the EPHESUS trial criteria \[16\] or having a documented allergy or adverse reaction to betablocker and/or RAAS inhibition.
- Age 18 years or older.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| Cincinnati VA Medical Center, Cincinnati, OH Coordinator of this site? Confirm its status | Cincinnati | United States | Unknown status |
| Louis Stokes VA Medical Center, Cleveland, OH Coordinator of this site? Confirm its status | Cleveland | United States | Unknown status |
| Providence VA Medical Center, Providence, RI Coordinator of this site? Confirm its status | Providence | United States | Unknown status |
| Hunter Holmes McGuire VA Medical Center, Richmond, VA Coordinator of this site? Confirm its status | Richmond | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.